One innovative approach engineered proteins capable of concurrently targeting 4-1BB and tumor stroma or tumor antigens, effectively overcoming the potential side effects of 4-1BB agonists and yielding remarkable tumor regression in murine models [37]. The gene discussed is TNFRSF9; the disease is neoplasm.